CL2022000781A1 - Tratamientos cognitivos medicinales - Google Patents
Tratamientos cognitivos medicinalesInfo
- Publication number
- CL2022000781A1 CL2022000781A1 CL2022000781A CL2022000781A CL2022000781A1 CL 2022000781 A1 CL2022000781 A1 CL 2022000781A1 CL 2022000781 A CL2022000781 A CL 2022000781A CL 2022000781 A CL2022000781 A CL 2022000781A CL 2022000781 A1 CL2022000781 A1 CL 2022000781A1
- Authority
- CL
- Chile
- Prior art keywords
- medicinal
- healthy subject
- cognitive
- treatments
- cognitively healthy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019903681A AU2019903681A0 (en) | 2019-09-30 | Medicinal cognitive treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022000781A1 true CL2022000781A1 (es) | 2022-11-18 |
Family
ID=75336310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022000781A CL2022000781A1 (es) | 2019-09-30 | 2022-03-29 | Tratamientos cognitivos medicinales |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230000843A1 (enExample) |
| EP (1) | EP4037684A4 (enExample) |
| JP (1) | JP2022550221A (enExample) |
| KR (1) | KR20220080116A (enExample) |
| CN (1) | CN114761005A (enExample) |
| AU (1) | AU2020359291B2 (enExample) |
| CA (1) | CA3152902A1 (enExample) |
| CL (1) | CL2022000781A1 (enExample) |
| IL (1) | IL292739B2 (enExample) |
| MX (1) | MX2022003845A (enExample) |
| WO (1) | WO2021062472A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI855081B (zh) * | 2019-05-24 | 2024-09-11 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| IL303170A (en) * | 2020-11-25 | 2023-07-01 | Sage Therapeutics Inc | 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders |
| WO2024073794A1 (en) * | 2022-10-07 | 2024-04-11 | Actinogen Medical Limited | SUBJECT SELECTION FOR 11β-HSD1 INHIBITOR TREATMENT |
| CN121969372A (zh) * | 2023-10-03 | 2026-05-01 | 射线质医疗有限公司 | 片剂制剂 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2477983T3 (en) * | 2009-09-16 | 2015-06-29 | Univ Edinburgh | (4-phenyl-piperidin-1-yl) - [5-1H-pyrazol-4-yl) -thiophene-3-yl] -METHANONFORBINDELSER AND THEIR USE |
| BR112012027640B1 (pt) * | 2010-04-29 | 2021-08-03 | The University Of Edinburgh | Composto, composição farmacêutica, e, métodos de preparar uma composição farmacêutica, de inibir a função da 11beta-hidroxiesteroide desidrogenase do tipo 1 |
-
2020
- 2020-09-30 EP EP20870933.7A patent/EP4037684A4/en active Pending
- 2020-09-30 AU AU2020359291A patent/AU2020359291B2/en active Active
- 2020-09-30 JP JP2022544867A patent/JP2022550221A/ja active Pending
- 2020-09-30 CA CA3152902A patent/CA3152902A1/en active Pending
- 2020-09-30 CN CN202080082617.6A patent/CN114761005A/zh active Pending
- 2020-09-30 US US17/764,922 patent/US20230000843A1/en active Pending
- 2020-09-30 WO PCT/AU2020/051043 patent/WO2021062472A1/en not_active Ceased
- 2020-09-30 KR KR1020227014330A patent/KR20220080116A/ko not_active Ceased
- 2020-09-30 MX MX2022003845A patent/MX2022003845A/es unknown
-
2022
- 2022-03-29 CL CL2022000781A patent/CL2022000781A1/es unknown
- 2022-05-03 IL IL292739A patent/IL292739B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114761005A (zh) | 2022-07-15 |
| WO2021062472A1 (en) | 2021-04-08 |
| AU2020359291B2 (en) | 2026-04-30 |
| US20230000843A1 (en) | 2023-01-05 |
| KR20220080116A (ko) | 2022-06-14 |
| JP2022550221A (ja) | 2022-11-30 |
| AU2020359291A1 (en) | 2022-04-21 |
| EP4037684A1 (en) | 2022-08-10 |
| MX2022003845A (es) | 2022-06-22 |
| CA3152902A1 (en) | 2021-04-08 |
| IL292739B2 (en) | 2026-08-01 |
| IL292739B1 (en) | 2026-04-01 |
| EP4037684A4 (en) | 2023-11-01 |
| IL292739A (en) | 2022-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PY2126213A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| CO2023000199A2 (es) | Péptidos funcionalizados como agentes antivirales | |
| CO2026005655A2 (es) | Inhibidor de pan-kras y uso del mismo en medicinas | |
| MX2022000143A (es) | Metodos novedosos. | |
| CO2020015758A2 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| MX2023002024A (es) | Métodos de tratamiento con modulador de miosina. | |
| ECSP22089498A (es) | Inhibidores de il4i1 y métodos de uso | |
| CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
| DOP2023000060A (es) | Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención | |
| MX370361B (es) | Preparación farmacéutica que contiene compuesto de ácido piridilaminoacético. | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| CR20190201A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
| PY1944026A (es) | Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias | |
| DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| CO2025018532A2 (es) | Un método para el tratamiento de tumores sólidos con un conjugado anticuerpo-fármaco dirigido a claudina 18.2 | |
| CL2025003377A1 (es) | Tratamiento de afecciones inflamatorias que comprende imu-856. | |
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| MX2022007854A (es) | Derivados del benzimidazol para el tratamiento y/o la prevención de enfermedades y trastornos mediados por el nlrp3. | |
| CL2021003303A1 (es) | Tratamiento para sinucleinopatías. | |
| UY39593A (es) | Tratamiento para tumores sólidos malignos | |
| BR112022005980A2 (pt) | Método para prevenir e/ou tratar declínio cognitivo em um sujeito cognitivamente saudável, composto, e, uso de um composto | |
| CL2025000332A1 (es) | Tratamiento de la urticaria con inhibidores de jak. |